These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35639870)

  • 1. Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.
    Fusaroli M; Raschi E; Giunchi V; Menchetti M; Rimondini Giorgini R; De Ponti F; Poluzzi E
    Int J Neuropsychopharmacol; 2022 Sep; 25(9):727-736. PubMed ID: 35639870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study.
    Fusaroli M; Giunchi V; Battini V; Gringeri M; Rimondini R; Menchetti M; Radice S; Pozzi M; Nobile M; Clementi E; De Ponti F; Carnovale C; Raschi E; Poluzzi E
    Psychiatry Clin Neurosci; 2023 Mar; 77(3):160-167. PubMed ID: 36436204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs.
    Moore TJ; Glenmullen J; Mattison DR
    JAMA Intern Med; 2014 Dec; 174(12):1930-3. PubMed ID: 25329919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
    Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
    CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list.
    Fusaroli M; Raschi E; Contin M; Sambati L; Menchetti M; Fioritti A; Poluzzi E
    Parkinsonism Relat Disord; 2021 Sep; 90():79-83. PubMed ID: 34399162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole and Other Third-Generation Antipsychotics as a Risk Factor for Impulse Control Disorders: A Systematic Review and Meta-Analysis.
    Williams BD; Lee K; Ewah SO; Neelam K
    J Clin Psychopharmacol; 2024 Jan-Feb 01; 44(1):39-48. PubMed ID: 38011021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation?
    Lertxundi U; Hernandez R; Medrano J; Domingo-Echaburu S; Garcia M; Aguirre C
    Int Clin Psychopharmacol; 2018 Jan; 33(1):56-58. PubMed ID: 28777129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotics and obsessive-compulsive disorder/obsessive-compulsive symptoms: A pharmacovigilance study of the FDA adverse event reporting system.
    Burk BG; DiGiacomo T; Polancich S; Pruett BS; Sivaraman S; Birur B
    Acta Psychiatr Scand; 2023 Jul; 148(1):32-46. PubMed ID: 37194481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole.
    Peterson E; Forlano R
    Australas Psychiatry; 2017 Dec; 25(6):614-616. PubMed ID: 28696131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study.
    Zazu L; Morera-Herreras T; Garcia M; Aguirre C; Lertxundi U
    Eur Neuropsychopharmacol; 2021 Sep; 50():107-111. PubMed ID: 34082277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase.
    De Wit LE; Wilting I; Souverein PC; van der Pol P; Egberts TCG
    Eur Neuropsychopharmacol; 2022 May; 58():30-38. PubMed ID: 35189453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole and its adverse effects in the form of impulsive-compulsive behaviors: A systematic review of case reports.
    Akbari M; Jamshidi S; Sheikhi S; Alijani F; Kafshchi P; Taylor D
    Psychopharmacology (Berl); 2024 Feb; 241(2):209-223. PubMed ID: 38227009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.
    Corponi F; Fabbri C; Bitter I; Montgomery S; Vieta E; Kasper S; Pallanti S; Serretti A
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):971-985. PubMed ID: 31255396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
    Hope J; Castle D; Keks NA
    Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotics and risk of QT prolongation: a pharmacovigilance study.
    Bordet C; Garcia P; Salvo F; Touafchia A; Galinier M; Sommet A; Montastruc F
    Psychopharmacology (Berl); 2023 Jan; 240(1):199-202. PubMed ID: 36515735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
    Citrome L
    Int J Clin Pract; 2015 Nov; 69(11):1211-20. PubMed ID: 26477545
    [No Abstract]   [Full Text] [Related]  

  • 17. [Aripiprazole, gambling disorder and compulsive sexuality].
    Mété D; Dafreville C; Paitel V; Wind P
    Encephale; 2016 Jun; 42(3):281-3. PubMed ID: 26923999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
    Szarfman A; Tonning JM; Levine JG; Doraiswamy PM
    Pharmacotherapy; 2006 Jun; 26(6):748-58. PubMed ID: 16716128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists: A Retrospective Cohort Study.
    Sodhi M; Etminan M; Carleton B; Samii A
    J Clin Psychopharmacol; 2019; 39(6):675-676. PubMed ID: 31688453
    [No Abstract]   [Full Text] [Related]  

  • 20. Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA Adverse Event Reporting System database (FAERS).
    Stamoula E; Stamatellos VP; Vavilis T; Dardalas I; Papazisis G
    Expert Opin Drug Saf; 2024 Feb; 23(2):239-245. PubMed ID: 37589503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.